Unmet Needs in HER2-Mutant NSCLC

In this episode, panelists identify ongoing challenges in delivering optimal care to patients with HER2-mutant non-small cell lung cancer. The discussion centers on the disparity between academic and community practices, particularly in the consistent use and timely implementation of comprehensive molecular testing. Experts highlight that, while advanced centers often perform multi-gene next-generation sequencing (NGS) reflexively and concurrently with both tissue and blood samples, many community sites lack the same frequency or speed in adopting these practices. This results in potential delays or omissions in identifying actionable HER2 mutations, which can directly impact treatment options. The episode also addresses possible causes for these gaps, including educational barriers and demographic differences that may affect testing rates. Overall, the group emphasizes the critical need to improve both education and infrastructure, ensuring that all patients—regardless of location—have equitable and prompt access to guideline-based testing and emerging targeted therapies.